179 related articles for article (PubMed ID: 28778441)
21. Exploring the Transition of Human α-Synuclein from Native to the Fibrillar State: Insights into the Pathogenesis of Parkinson's Disease.
Fazili NA; Naeem A
J Fluoresc; 2016 Sep; 26(5):1659-69. PubMed ID: 27365127
[TBL] [Abstract][Full Text] [Related]
22. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
23. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
Kim S; Seo JH; Suh YH
Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S9-13. PubMed ID: 15109581
[TBL] [Abstract][Full Text] [Related]
24. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
[TBL] [Abstract][Full Text] [Related]
25. Roles for the adaptive immune system in Parkinson's and Alzheimer's diseases.
Lindestam Arlehamn CS; Garretti F; Sulzer D; Sette A
Curr Opin Immunol; 2019 Aug; 59():115-120. PubMed ID: 31430650
[TBL] [Abstract][Full Text] [Related]
26. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
27. Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease.
Woulfe JM; Gray MT; Gray DA; Munoz DG; Middeldorp JM
Parkinsonism Relat Disord; 2014 Jul; 20(7):685-94. PubMed ID: 24726430
[TBL] [Abstract][Full Text] [Related]
28. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
[TBL] [Abstract][Full Text] [Related]
29. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.
Zhou J; Broe M; Huang Y; Anderson JP; Gai WP; Milward EA; Porritt M; Howells D; Hughes AJ; Wang X; Halliday GM
Acta Neuropathol; 2011 Jun; 121(6):695-704. PubMed ID: 21400129
[TBL] [Abstract][Full Text] [Related]
30. Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.
Brudek T; Winge K; Folke J; Christensen S; Fog K; Pakkenberg B; Pedersen LØ
Mol Neurodegener; 2017 Jun; 12(1):44. PubMed ID: 28592329
[TBL] [Abstract][Full Text] [Related]
31. L-dopa increases α-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.
Schmitt I; Kaut O; Khazneh H; deBoni L; Ahmad A; Berg D; Klein C; Fröhlich H; Wüllner U
Mov Disord; 2015 Nov; 30(13):1794-801. PubMed ID: 26173746
[TBL] [Abstract][Full Text] [Related]
32. Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson's disease.
Su Y; Shi C; Wang T; Liu C; Yang J; Zhang S; Fan L; Zheng H; Li X; Luo H; Zhang S; Hu Z; Fan Y; Hao X; Zhang C; Song B; Mao C; Xu Y
J Neurol; 2022 Dec; 269(12):6386-6394. PubMed ID: 35895134
[TBL] [Abstract][Full Text] [Related]
33. Reduced T helper and B lymphocytes in Parkinson's disease.
Stevens CH; Rowe D; Morel-Kopp MC; Orr C; Russell T; Ranola M; Ward C; Halliday GM
J Neuroimmunol; 2012 Nov; 252(1-2):95-9. PubMed ID: 22910543
[TBL] [Abstract][Full Text] [Related]
34. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
Zhang QS; Heng Y; Yuan YH; Chen NH
Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
[TBL] [Abstract][Full Text] [Related]
35. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.
Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA
ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550
[TBL] [Abstract][Full Text] [Related]
36. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
37. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
Ulusoy A; Decressac M; Kirik D; Björklund A
Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
[TBL] [Abstract][Full Text] [Related]
38. The association between infectious burden and Parkinson's disease: A case-control study.
Bu XL; Wang X; Xiang Y; Shen LL; Wang QH; Liu YH; Jiao SS; Wang YR; Cao HY; Yi X; Liu CH; Deng B; Yao XQ; Xu ZQ; Zhou HD; Wang YJ
Parkinsonism Relat Disord; 2015 Aug; 21(8):877-81. PubMed ID: 26037459
[TBL] [Abstract][Full Text] [Related]
39. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Spiro AS; Furuta A; Cooper A; Garner B; Kabuta T; Halliday GM
Mov Disord; 2015 Oct; 30(12):1639-47. PubMed ID: 25594542
[TBL] [Abstract][Full Text] [Related]
40. The role of T cells in the pathogenesis of Parkinson's disease.
Chen Z; Chen S; Liu J
Prog Neurobiol; 2018 Oct; 169():1-23. PubMed ID: 30114440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
